Biblioteca Humberto Rosselli Quijano
Información del autor
Autor Cedric Cunanan |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium / Robert Lynn Horne en Journal of Clinical Psychopharmacology, Año 2003 - Vol. 23 - No. 2 (Abril)
[artículo]
Título : Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium Tipo de documento: texto impreso Autores: Robert Lynn Horne, Autor ; Cedric Cunanan, Autor Fecha de publicación: 2023 Artículo en la página: pp. 176-181 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antimaníacos, Trastornos mentales - diagnóstico, Acido Valproico. Resumen: This study evaluated the safety and efficacy of divalproex sodium extended-release (ER) when patients were switched from therapy with divalproex sodium delayed-release (DR) to divalproex sodium ER. This open-label, 7-day study included 55 patients with bipolar disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, dementia, or intermittent explosive disorder. Link: ./index.php?lvl=notice_display&id=31035
in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 2 (Abril) . - pp. 176-181[artículo] Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium [texto impreso] / Robert Lynn Horne, Autor ; Cedric Cunanan, Autor . - 2023 . - pp. 176-181.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2003 - Vol. 23 - No. 2 (Abril) . - pp. 176-181
Palabras clave: Antimaníacos, Trastornos mentales - diagnóstico, Acido Valproico. Resumen: This study evaluated the safety and efficacy of divalproex sodium extended-release (ER) when patients were switched from therapy with divalproex sodium delayed-release (DR) to divalproex sodium ER. This open-label, 7-day study included 55 patients with bipolar disorder, major depression, schizophrenia, schizoaffective disorder, Alzheimer’s disease, dementia, or intermittent explosive disorder. Link: ./index.php?lvl=notice_display&id=31035